Accueil A new Institute dedicated to combating Leukemia

A new Institute dedicated to combating Leukemia

Launch of the Leukemia Institute

Who we are

Who we are

The Leukemia Institute is a University Hospital Institute founded in 2023 by the Assistance Publique–Hôpitaux de Paris, INSERM, the Collège de France, and Université Paris Cité, and hosted by the Université Paris Cité Foundation (FUPC). It embodies an unprecedented collaborative approach, bringing together clinical and scientific expertise around a shared goal: transforming the care of patients with acute leukemias and related disorders.

By uniting research teams and clinical departments within an integrated structure, the Institute’s mission is to foster synergies and accelerate the translation of scientific discoveries into tangible medical advances, always keeping patients at the heart of its priorities.

The Institute aims to become a world-leading reference in the field of leukemia, building on its scientific and medical excellence, strategic partnerships, and innovative training programs.

The Leukemia Institute in figures

1st

Leukemia Treatment and Research Center

16

Research Teams

10

Clinical Departments

4

Medical Biology Laboratories

Four missions of the Leukemia Institute

Research

16 research teams focusing on fundamental, translational, clinical research and improvement of patient care pathways

Care

14 clinical department for children, adolescents, adults, and seniors

Education

A unique range of training courses dedicated to students, researchers, healthcare professionals and industry professionals

Innovation

Innovative patents and industrial collaborations, particularly with our drug screening platform.

Our objectives

The Leukemia Institute is built around four strategic objectives:

1 Identify predisposing factors for leukemia and develop preventive treatments

2 Understand the heterogeneity of leukemia and design innovative therapies

3 Explore the mechanisms of treatment resistance

4 Improve patients’ quality of life

Stéphanie CHAMBAUD

Clinical Departments

Department of senior hematology, Lionel Adès

Saint-Louis Hospital

1 avenue Claude Vellefaux 75010 Paris

Outpatient Hemato-oncogenetics Unit, Marie Sébert

Saint-Louis Hospital

1 avenue Claude Vellefaux 75010 Paris

Adolescent and Young Adult Unit, Nicolas Boissel

Saint-Louis Hospital

1 avenue Claude Vellefaux 75010 Paris

Department of clinical hematology and cell therapy, Thorsten Braun

Avicenne Université Sorbonne Paris Nord Hospital

125 Route de Stalingrad 93000 Bobigny

Department of Pharmacology and Clinical Investigations, Vincent Lévy

Saint-Louis Hospital

1 avenue Claude Vellefaux 75010 Paris

Hematology Transplant Unit , Régis Peffault de Latour

Saint-Louis Hospital

1 avenue Claude Vellefaux, 75010 Paris

Department of adult hematology, Emmanuel Raffoux

Saint-Louis Hospital

1 avenue Claude Vellefaux 75010 Paris

Department of clinical haematology

Cochin–Port Royal Hospital

27 rue du Faubourg Saint Jacques – 75014 Paris

Department of Paediatric Hematology and Immunology, Jean-Hugues Dalle

Robert-Debré Hospital

48 boulevard Sérurier 75019 Paris

History of hematology on the Saint-Louis Hospital campus

1945

First remission of leukemia achieved by Professor Jean Bernard and his team at Saint-Louis Hospital

1980

Professor Jean Dausset awarded the Nobel Prize for the discovery of tissue groups enabling bone marrow transplantation

1980

International morphological classification of acute leukemias developed by George Flandrin and Marie-Thérèse Daniel

1989

World’s first umbilical cord blood transplant performed by Professor Eliane Gluckman

1990

Identification of the PML gene by Professor Hugues de Thé

1990

Treatment of acute promyelocytic leukemia with retinoic acid developed by Professors Laurent Degos and Pierre Fenaux

1990

Development of national cooperative groups for the treatment of acute myeloid and lymphoid leukemias led by Professor Hervé Dombret

1998

Demonstration of the predictive value of minimal residual disease by Professors Hélène Cavé and Bernard Grandchamp

2000

Advances in molecular hematology at Saint-Louis, Necker, and Robert-Debré Hospitals, contributing to the understanding of the molecular heterogeneity of leukemias

2016

First French child with refractory leukemia treated with CAR-T cells at Robert-Debré Hospital by Professor André Baruchel

2016

New insights into the heterogeneity of inherited aplastic anemias

2019

Creation of the first national multidisciplinary molecular boards for acute leukemias

2020

Innovative treatments for aplastic anemia with PNH

2023

Creation of the Leukemia Institute, recognized as a University Hospital Institute under the France 2030 national plan

View more

Host foundation and founding members

Frequently asked questions

What is a University Hospital Institute ?

University Hospital Institutes aim to promote translational research — research that rapidly moves from the laboratory to the patient’s bedside.

They bring together clinical, scientific, and technological expertise around a specific medical theme to accelerate progress in care and innovation.
Since 2010, 19 IHUs have been established in France.

The Leukemia Institute was designated as an IHU under the France 2030 national plan and received €30 million in funding.

When was the Leukemia Institute established?

The Institute was created in 2023 as part of the France 2030 national investment program.
It was selected for its ambitious scientific project and recognized expertise in hematology.

Who are the founding members?

The Leukemia Institute was founded by the Assistance Publique–Hôpitaux de Paris (AP-HP), INSERM, the Collège de France, and Université Paris Cité.
The IHU is hosted by the Université Paris Cité Foundation (FUPC).